Results 91 to 100 of about 181,344 (173)

LYMPHOCYTES IN PATIENTS WITH CHRONIC ACTIVE EPSTEIN-BARR VIRUS INFECTION EXHIBITED ELEVATED PD-1/PD-L1 EXPRESSION AND A PREVAILING TH2 IMMUNE RESPONSE.

Mediterranean Journal of Hematology and Infectious Diseases
Background And Objectives: Chronic active Epstein-Barr virus infection (CAEBV) is a lymphoproliferative disorder characterized by the increased numbers of EBV-infected T/natural killer (NK) cells and ongoing symptoms resembling infectious mononucleosis.
kang sun
doaj   +1 more source

SUPREME-HN: a retrospective biomarker study assessing the prognostic value of PD-L1 expression in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck. [PDF]

, 2019
BACKGROUND:Programmed cell death ligand-1 (PD-L1) expression on tumor cells (TCs) is associated with improved survival in patients with head and neck squamous cell carcinoma (HNSCC) treated with immunotherapy, although its role as a prognostic factor is ...
Baste, Neus, Clayburgh, Daniel, Cohen, Ezra EW, Fountzilas, George, Fujii, Takashi, Khaliq, Asud, Kim, Edward S, Lin, Derrick, Lipworth, Loren, Mehlhorn, Holger, Melillo, Giovanni, Pai, Sara I, Resteghini, Carlo, Shara, Nawar, Shire, Norah, Stokes, Michael, Twumasi-Ankrah, Philip, Wang, Huifen, Wildsmith, Sophie, Zhang, Jun   +19 more
core   +1 more source

Blocking of the B7-CD28 pathway increases the capacity of FasL⁺ (CD95L⁺) dendritic cells to kill alloactivated T cells [PDF]

, 1997
AW Thomson, D Vremec, DH Lynch, DH Munn, DR Green, F Fu, G Süss, HT Lau, L Lu, L Lu, L Lu, L Tian, L Zheng, LH Boise, M.R. Alderson, MX Wu, RM Steinman, S Hauschildt, S-T Ju, S. Nagata, SA Mccarthy, TS Griffith, Y Gavrieli   +22 more
core   +1 more source

Personalized Immunotherapy Achieves Complete Response in Metastatic Adenoid Cystic Carcinoma Despite Lack of Conventional Biomarkers

Current Oncology
There is currently no effective treatment strategy for recurrent/metastatic adenoid cystic carcinoma (R/M ACC). Furthermore, recent single-agent and combination immunotherapy trials have failed in unselected ACC cohorts, unlike non-ACC salivary gland ...
Ünal Metin Tokat, Ashkan Adibi, Esranur Aydın, Eylül Özgü, Şevval Nur Bilgiç, Onur Tutar, Merve Özbek Doğançay, İrem Demiray, Mutlu Demiray   +8 more
doaj   +1 more source

Serum levels of soluble programmed cell death protein 1 and soluble programmed cell death protein ligand 2 are increased in systemic lupus erythematosus and associated with the disease activity

Serum levels of soluble programmed cell death protein 1 and soluble programmed cell death protein ligand 2 are increased in systemic lupus erythematosus and associated with the disease activity
博士(医学) 乙第3130号(主論文の要旨、要約、審査結果の要旨)
openaire  

Basal cell carcinoma: Management of advanced or metastatic cancer with checkpoint inhibitors and concurrent paradoxical development of new superficial tumors. [PDF]

, 2020
Cohen, Philip R, Kurzrock, Razelle
core   +1 more source

Correlation of E-cadherin, vimentin, CD206, programmed cell death receptor 1, and programmed cell death ligand 1 expressions with clinicopathological factors and prognosis in oral squamous cell carcinoma. [PDF]

J Int Med Res
Lai ZY, Ma J, Yin JY, Zhu XA, Zhou JP, Tao DT.   +5 more
europepmc   +1 more source

Compartment-specific immune and tumor markers associated with clinical outcomes in patients with and without sarcomatoid/rhabdoid renal cell carcinoma treated with ipilimumab and nivolumab. [PDF]

ESMO Open
Savion-Gaiger N, Perales O, Su DG, Bar-Ziv D, Challa P, Djureinovic D, Yi I, Adeniran A, Kluger H, Schoenfeld D.   +9 more
europepmc   +1 more source

Fianlimab, a human lymphocyte activation gene-3 monoclonal antibody, in combination with cemiplimab: Tumor-specific expansion cohorts in advanced malignancies. [PDF]

Cancer
Kim TM, Williamson SK, Papadopoulos KP, Hamid O, Dy GK, McDermott R, Birnbaum A, Kaczmar JM, Lakhani N, Rischin D, Sarker D, Dowlati A, Zhu XH, Malhotra J, Pouliot JF, Mani J, Brennan L, Fang F, Chen S, Salvati M, Lowy I, Khaled A, Lewis KD, Kroog G, Fury MG, Cho BC.   +25 more
europepmc   +1 more source

Simplified perioperative serplulimab and chemotherapy for resectable squamous NSCLC: a phase II trial with biomarker analysis. [PDF]

J Immunother Cancer
Fu F, Wu H, Deng C, Chen H, Huang Q, Yuan C, Ding X, Ye T, Zhou Y, Chen S, Sun Y, Zhang Y, Xiang J, Wang S, Li Y, Li B, Lu Y, Zhang Y, Hu H, Chen H.   +19 more
europepmc   +1 more source